Table 1.
Demographics, comorbidities, pharmacological therapy, cardiovascular risk factors, and exercise performance.
| Anthropometrics | M (SD) |
|---|---|
| Height (cm) | 172.3 (7.8) |
| Weight (kg) | 88.09 (16.66) |
| Waist circumference (cm) | 105.3 (12.6) |
| Hip circumference (cm) | 106.1 (7.6) |
| Clinical Data | M (SD) or Me (Q1, Q3) |
| LVEF (%) | 53 (10) |
| Time from clinical event to inclusion in CR (months) | 2.0 (1.5, 2.0) |
| Myocardial Infarction | f (%) |
| NSTEMI | 20 (46.51) |
| STEMI | 20 (46.51) |
| Unstable AP | 3 (6.98) |
| Comorbidities and Risk Factors | f (%) |
| Arterial hypertension | 31 (72.09) |
| Hyperlipidemia | 35 (81.40) |
| Diabetes | 6 (13.95) |
| Atrial fibrillation | 3 (6.989) |
| Thyroid disease | 4 (9.30) |
| Renal disease | 3 (6.98) |
| Smoking | f (%) |
| Non-smoker | 14 (32.56) |
| Ex-smoker | 21 (48.84) |
| Smoker | 8 (18.60) |
| Pharmacological Therapy | f (%) |
| Aspirin | 41 (95.35) |
| Beta blocker | 43 (100.00) |
| ACE inhibitor/ARB | 41 (95.35) |
| Statin | 43 (100.00) |
| Antiplatelet drug | 42 (97.67) |
| Anticoagulation drug | 2 (4.65) |
| Diuretic | 5 (11.63) |
| Exercise Characteristics | |
| Aerobic Capacity | M (SD) or Me (Q1, Q3) |
| Power output (W) | 128 (45) |
| VO2 max (L/min) | 1.58 (0.54) |
| VCO2 max (L/min) | 1.69 (0.63) |
| VO2 max (mL/kg/min) | 18.10 (5.27) |
| Respiratory exchange ratio | 1.05 (0.09) |
| Ve/VCO2 slope | 28.22 (26.28, 31.85) |
| Maximal Leg Strength, M (SD) | M (SD) or Me (Q1, Q3) |
| Submaximal 1-RM | 122 (45) |
| Number of reps at submaximal 1-RM | 4 (3,5) |
| Calculated 1-RM (kg) | 132 (48) |
| 40% 1-RM (kg) | 53 (19) |
| 80% 1-RM (kg) | 105 (38) |
Me (Q1, Q3), median (first quartile, third quartile); LVEF: left ventricular ejection fraction; (N)STEMI: (non-) ST segment-elevated myocardial infarction; AP: angina pectoris; ACE: angiotensin-converting-enzyme; ARB: angiotensin II receptor blockers; VO2: maximal oxygen consumption; Ve/VCO2: ventilation/carbon dioxide production ratio; 1-RM: one-repetition maximum.